Justin Zelin
Stock Analyst at BTIG
(1.40)
# 3,150
Out of 4,818 analysts
37
Total ratings
20.59%
Success rate
-3.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.69 | +123.05% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $17.84 | +135.49% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.22 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $18.84 | +229.17% | 2 | Jul 9, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $90 | $4.63 | +1,843.84% | 1 | Jul 8, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.63 | +636.20% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $0.09 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $25.79 | +384.68% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $7.18 | +276.04% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $1,000 → $800 | $1.33 | +60,050.38% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $29.86 | +204.76% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.60 | +1,562.79% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $0.91 | +1,658.05% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $6.62 | +458.91% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $13.01 | +169.02% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $34.30 | +162.39% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $6.37 | +386.66% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $61.30 | -74.71% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.98 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.97 | +407.61% | 3 | Nov 16, 2022 |
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.69
Upside: +123.05%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $17.84
Upside: +135.49%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.22
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $18.84
Upside: +229.17%
Jasper Therapeutics
Jul 8, 2024
Initiates: Buy
Price Target: $90
Current: $4.63
Upside: +1,843.84%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.63
Upside: +636.20%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.09
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $25.79
Upside: +384.68%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $7.18
Upside: +276.04%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.33
Upside: +60,050.38%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $29.86
Upside: +204.76%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.60
Upside: +1,562.79%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $0.91
Upside: +1,658.05%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $6.62
Upside: +458.91%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $13.01
Upside: +169.02%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $34.30
Upside: +162.39%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $6.37
Upside: +386.66%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $61.30
Upside: -74.71%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.98
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.97
Upside: +407.61%